XLock Biosciences | Advancing Breakthrough Drug Delivery Technologies
Harnessing the potential of chemokine biology to unlock new therapeutic possibilities in immunology and oncology
About XLock Biosciences: Revolutionizing Drug Delivery
About Us
XLock is built on the vision that chemokine biology holds the key to next-generation precision therapies in immunology and oncology. By applying deep expertise in protein engineering and immune system modulation, we are exploring new ways to selectively target disease-driving pathways.
Our chemokine-targeting platform is designed to enhance specificity, reduce off-target effects, and expand the potential of precision medicine.
Deep Domain Expertise
De-Risked Development & Early Validation
Built for Depth & Scalability
Meet Our Team: Scientific Leadership Driving Innovation
Team
Francis Peterson, PhD, is a Professor of Biochemistry at the Medical College of Wisconsin, with over 20 years of research experience in cytokine and chemokine protein design and structure. His work has resulted in over 100 publications and 70 protein structures, including potential treatments for inflammatory diseases like cancer and psoriasis.
Dr. Bill Clarke is a physician and molecular pharmacologist. He has over 30 years of experience in pharma and biotech, including as Director of Biological Sciences at GlaxoWellcome, EVP and Global Head of R and D at Amersham, and CEO of Cellectar. Most recently, Dr Clarke was Director of the Drug, Device and Diagnostic accelerator at Boston Children’s Hospital.
Brian Volkman is a Professor of Biochemistry at the Medical College of Wisconsin and is recognized for his contributions in the fields of structural genomics, protein dynamics and precision medicine. Engineered chemokines developed in his research lab have been licensed by multiple companies for therapeutic development.
Dr. Hwang is Professor and Chair of Dermatology at UC Davis and has over 25 years of experience as a physician-scientist in skin immunology. Supported by NIH as well as the National Psoriasis Foundation, he is recognized for his work in psoriasis pathogenesis.
Michael Dwinell, PhD, is the Hanis-Stepka-Rettig Endowed Chair in Cancer Research, professor of Microbiology & Immunology and Surgery and director of the Center for Immunology. He has extensive leadership experience in multidisciplinary research teams that span the breadth of academic biomedical research and education management. His NIH funded multidisciplinary research has centered on the pathophysiologic mechanisms of inflammation, tumor progression, and metastasis. His current research focuses on chemokines as pivotal immune messengers regulating the immune microenvironment, exploring innovative strategies to reorganize the immune microenvironment to overcome immune suppression and evasion in cancer.
Laura McOlash, B.S., has over 30 years of research experience at the Medical College of Wisconsin, focusing on the immune system in cancer and other diseases. Her understanding of lab operations, clinical trials, and focused collaboration contributes significantly to the company’s research success.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Our Technology: Unlocking Precision Drug Delivery
Our Science and Approach
Chemokines are essential regulators of immune function and cancer progression. However, current therapeutic approaches lack precision, leading to off-target effects and limited efficacy.
XLock is pioneering a new way forward by designing molecules that selectively modulate chemokine activity to address complex disease mechanisms in immunology and oncology.
Precision Engineering
Developing therapies that achieve high specificity in targeting chemokine-driven pathways.
Minimizing Off-Target Effects
Enhancing selectivity to optimize therapeutic potential.
Expanding Possibilities
Unlocking new applications for chemokine-based therapies in oncology and immune disorders.
Our Pipeline: Advancing Novel Drug Delivery Solutions
Pipeline
XLock is developing a pipeline of chemokine-targeted therapies designed to address significant gaps in immunology and oncology. Our lead program, XL106, is advancing toward clinical development, with additional programs following closely behind.
.webp)
Focused on Early Clinical Proof-of-Concept
Current Focus & Future Applications
With a commitment to scientific rigor, XLock is building a scalable, high-impact pipeline aimed at redefining treatment strategies in immunology and oncology
News
Contact Us: Partner with XLock Biosciences
Contact Us
662 South 94th Place
Milwaukee, WI 53214
.png)
.png)
